Publication:
Effectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24

Simple item page
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorMazagatos, Clara
dc.contributor.authorLorusso, Nicola
dc.contributor.authorBasile, Luca
dc.contributor.authorMartínez-Pino, Isabel
dc.contributor.authorCorpas-Burgos, Francisca
dc.contributor.authorBatalla Rebolla, Noa
dc.contributor.authorRumayor-Zarzuelo, Mercedes Belén
dc.contributor.authorAndreu Ivorra, Blanca
dc.contributor.authorGiménez Duran, Jaume
dc.contributor.authorCastrillejo, Daniel
dc.contributor.authorGuiu Cañete, Inés
dc.contributor.authorHuerta Huerta, Marta
dc.contributor.authorGarcía Becerril, Marta
dc.contributor.authorRamos Marín, Violeta
dc.contributor.authorCasas Flecha, Inmaculada
dc.contributor.authorPozo Sanchez, Francisco
dc.contributor.authorMonge Corella, Susana
dc.contributor.authorSiVIRA group
dc.contributor.funderUnión Europea. European Centre for Disease Prevention and Control (ECDC)
dc.date.accessioned2024-10-30T14:00:47Z
dc.date.available2024-10-30T14:00:47Z
dc.date.issued2024-10
dc.description.abstractDuring 2023/24, all children aged 6 to 59 months were targeted for seasonal influenza vaccination in Spain nationally. Using a test-negative case-control design with sentinel surveillance data, we estimated adjusted influenza vaccine effectiveness (IVE) against any influenza type to be 70% (95% confidence interval (CI): 51 to 81%) for primary care patients with acute respiratory illness (ARI) and 77% (95% CI: 21 to 93%) for hospitalised patients with severe ARI. In primary care, where most subtyped viruses (61%; 145/237) were A(H1N1), adjusted IVE was 77% (95% CI: 56 to 88%) against A(H1N1)pdm09.
dc.description.peerreviewedSí
dc.description.sponsorshipSome Autonomous Communities received funding from ECDC for the implementation of sentinel surveillance in Spain. Researchers at the National Centre of Epidemiology (Institute of Heath Carlos III) received funding from ECDC through the project “ECDC primary care network for Vaccine Effectiveness, Burden and Impact Studies and for Surveillance of Acute Respiratory Infections” Framework Contract n° ECDC/2021/019 and “ECDC Hospital network for Vaccine Effectiveness, Burden and Impact Studies and for Surveillance of Severe Acute Respiratory Infections” Framework Contract n° ECDC/2021/016 within the “Vaccine Effectiveness, Burden and Impact Studies (VEBIS) of COVID-19 and Influenza” platform.
dc.format.number40
dc.format.page2400618
dc.format.volume29
dc.identifier.citationEuro Surveill. 2024 Oct;29(40):2400618.
dc.identifier.doi10.2807/1560-7917.ES.2024.29.40.2400618
dc.identifier.e-issn1560-7917
dc.identifier.issn1025-496X
dc.identifier.journalEuro surveillance : bulletin Européen sur les maladies transmissibles = European communicable disease bulletin
dc.identifier.pubmedID39364601
dc.identifier.urihttps://hdl.handle.net/20.500.12105/25380
dc.language.isoeng
dc.publisherEuropean Centre for Disease Prevention and Control (ECDC)
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/ECDC/2021/016
dc.relation.publisherversionhttps://doi.org/10.2807/1560-7917.ES.2024.29.40.2400618
dc.repisalud.centroISCIII::Centro Nacional de Microbiología (CNM)
dc.repisalud.centroISCIII::Centro Nacional de Epidemiología (CNE)
dc.repisalud.institucionISCIII
dc.repisalud.instituteIIS::IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)
dc.rights.accessRightsopen access
dc.rights.licenseAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectChildren
dc.subjectInfluenza
dc.subjectTest-negative design
dc.subjectVaccine effectiveness
dc.subject.meshCase-Control Studies
dc.subject.meshChild, Preschool
dc.subject.meshFemale
dc.subject.meshHospitalization
dc.subject.meshHospitals
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshInfluenza A Virus, H1N1 Subtype
dc.subject.meshInfluenza A Virus, H3N2 Subtype
dc.subject.meshInfluenza B virus
dc.subject.meshInfluenza Vaccines
dc.subject.meshInfluenza, Human
dc.subject.meshMale
dc.subject.meshPrimary Health Care
dc.subject.meshSeasons
dc.subject.meshSentinel Surveillance
dc.subject.meshSpain
dc.subject.meshVaccination
dc.subject.meshVaccine Efficacy
dc.titleEffectiveness of influenza vaccines in children aged 6 to 59 months: a test-negative case-control study at primary care and hospital level, Spain 2023/24
dc.typeresearch article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublicationcd6d5fea-c769-479f-bdfa-1f76888459a3
relation.isAuthorOfPublicatione177bf8c-3734-480b-a2ae-4ae67491776c
relation.isAuthorOfPublicatione2df6e55-f1d3-423b-a72f-fd9a69cf5915
relation.isAuthorOfPublication5611ffc3-de88-4908-b20a-9a15a58c060a
relation.isAuthorOfPublicationa0bb4f4f-11f0-487e-bf93-0b13f90057cc
relation.isAuthorOfPublication.latestForDiscoverye177bf8c-3734-480b-a2ae-4ae67491776c
relation.isFunderOfPublication78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isFunderOfPublication.latestForDiscovery78e868cc-0192-448d-bcb1-98d618a7cee4
relation.isPublisherOfPublication844b1441-479c-4219-87e5-efc493160a02
relation.isPublisherOfPublication.latestForDiscovery844b1441-479c-4219-87e5-efc493160a02

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
EffectivenessInfluenzaVaccinesChildren_2024.pdf
Size:
272.41 KB
Format:
Adobe Portable Document Format
Download

Collections

Centro Nacional de Microbiología (CNM)
Centro Nacional de Epidemiología (CNE)
IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)